Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study

Kiltz, Uta; Sfikakis, Petros P.; Gaffney, Karl; Sator, Paul‐Gunther; Kiedrowski, Ralph von; Bounas, Andreas; Gullick, Nicola; Conrad, Curdin; Rigopoulos, Dimitrios; Lespessailles, Éric; Romanelli, Marco; Ghislain, Pierre-Dominique; Brandt‐Jürgens, Jan; Rashkov, Rasho; Aassi, Maher; Orsenigo, R.; Perella, Chiara; Pournara, Effie; Gathmann, Sven; Jagiello, Piotr; Veit, Justyna; Augustin, Matthias

doi:10.1007/s12325-020-01352-8

Cited by 29 publications

(32 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional studies would help to further elucidate the position of secukinumab in the real-world setting. The ongoing, longitudinal, observational SERENA study ( n = 2932) will assess the long-term (up to 5 years) retention of secukinumab in routine clinical practice across three indications (plaque psoriasis, AS and PsA) [ 62 ].…”

Section: Place Of Secukinumab In the Management Of Psoriatic Arthritismentioning

confidence: 99%

Secukinumab: A Review in Psoriatic Arthritis

Blair

2021

Drugs

View full text Add to dashboard Cite

Secukinumab (Cosentyx ® ) is a fully human monoclonal antibody that selectively targets interleukin (IL)-17A, a proinflammatory cytokine involved in the pathogenesis of psoriatic arthritis (PsA). Administered subcutaneously, the first-in-class anti-IL-17 agent is approved in numerous countries worldwide for the treatment of adults with active PsA. In the phase III FUTURE trials, secukinumab 150 or 300 mg improved the clinical signs and symptoms of PsA versus placebo in patients with active disease despite previous treatment with NSAIDs, biological disease-modifying anti-rheumatic drugs (bDMARDs) and/or tumour necrosis factor inhibitors (TNFi). The benefits of secukinumab were seen regardless of whether or not patients had received previous TNFi therapy, and were maintained during longer term (up to 5 years) treatment. In FUTURE 1 and 5, secukinumab inhibited structural joint damage and was associated with sustained low rates of radiographic progression through 1-3 years of treatment. Treatment with secukinumab improved physical function and health-related quality of life (HR-QOL) and was generally well tolerated, both in the short-and longer-term. In the head-to-head EXCEED trial, secukinumab did not quite attain statistical significance for superiority versus adalimumab in the joint domain. In conclusion, secukinumab is effective across all key PsA domains and is generally well tolerated, and thus represents a useful treatment alternative to TNFi and other bDMARDs in adult patients with active PsA.

show abstract

Section: Place Of Secukinumab In the Management Of Psoriatic Arthritismentioning

confidence: 99%

Secukinumab: A Review in Psoriatic Arthritis

Blair

2021

Drugs

View full text Add to dashboard Cite

show abstract

“…Some severe cases and exacerbations of Crohn's disease have also been described (8), so caution is recommended with its use. In terms of routine clinical practice, studies show a safety profile similar to that previously reported in RCTs and their long-term extension studies (9)(10)(11)(12), but information from real-world evidence studies is still scarce. Data on survival of biological therapy in PsA from the DANBIO registry showed a median survival of the first TNF inhibitor (TNFi) being 2.2 years and the second and third TNFi being 1.3 and 1.1 years, respectively.…”

Section: Introductionmentioning

confidence: 59%

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study

et al. 2021

View full text Add to dashboard Cite

Objectives: We aimed to evaluate the drug retention rate and safety of secukinumab (SEC) in patients with axial spondyloarthritis (AxSpA) and psoriatic arthritis (PsA) in a real clinical setting.Methods: This multicenter retrospective observational study included all AxSpA and PsA patients who received at least one dose of SEC. Adverse events (AE) and the drug retention rate were the main study outcomes. Drug survival was analyzed by Kaplan-Meier curves while predictive factors of discontinuation were evaluated using a Cox regression analysis. The weight of these associations was estimated by hazard ratio (HR) values.Results: We included 154 patients (59 PsA and 95 AxSpA). Mean disease duration was 6.5 years (IQR 2-8). Sixty-one percent of patients were treated with two or more biologics prior to SEC. The 1 and 2-year retention rates for SEC were 66 and 43%, respectively. The main causes of discontinuation were inefficacy (59%) and AE (36%). The factors associated with lower risk of discontinuation were male gender (HR 0.54, 95% CI 0.38-0.78 p = 0.001), obesity (HR 0.53, 95% CI 0.30-0.93 p = 0.027), hypertension (HR 0.55, 95% CI 0.30-0.93 p = 0.008), and diabetes (HR 0.42 95% CI 0.18-0.99 p = 0.047) while number of previous biologics and depression were predictors of discontinuation (HR 1.18, 95% CI 1.04-1.34 p = 0.011 and HR 2.53, 95% CI 1.61-3.96 p < 0.001).Conclusions: SEC showed a good retention rate in a population previously exposed to several biological therapies. As a novelty, cardiometabolic comorbidities were associated with better drug survival.

show abstract

“… 24 , 76 Here, we will focus on two key registries [EuroSpA and Consortium of Rheumatology Researchers of North America (CORRONA)] and studies (AQUILA and SERENA). 77 – 80 …”

Section: Secukinumabmentioning

confidence: 99%

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence

Braun

Kiltz

Bühring

et al. 2021

Therapeutic Advances in Musculoskeletal

Self Cite

View full text Add to dashboard Cite

Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease characterized by inflammation and new bone formation in the axial skeleton. AxSpA is considered a spectrum of disease that includes two subtypes identified by the Assessment in SpondyloArthritis International Society classification criteria, namely, radiographic (r-axSpA usually referred to as ankylosing spondylitis) and non-radiographic axSpA (nr-axSpA). Although the burden of disease appears similar between the two classified subtypes, the degree of inflammation, as assessed by magnetic resonance imaging and C-reactive protein, and the degree of new bone formation are significantly higher in r-axSpA than in nr-axSpA. Nevertheless, axSpA is considered one disease with different courses. International guidelines for the management of axSpA have outlined treatment goals focused on control of signs and symptoms, inflammation, prevention of progressive structural damage, preservation of physical function, normalization of social participation and improvement of quality of life. The pathogenesis of axSpA has not been completely elucidated to date. A strong link between human leukocyte antigen B27 and axSpA, however, has been identified, and the success of anti-tumour necrosis factor and anti-interleukin (IL)-17A therapy has highlighted some of the key pro-inflammatory cytokines involved. The anti-IL-17A monoclonal antibody secukinumab is approved for the treatment of ankylosing spondylitis and nr-axSpA in the European Union and United States. In this narrative review, we discuss data for secukinumab in axSpA from randomized controlled trials, including MEASURE trials in AS and PREVENT in nr-axSpA, and real-world evidence.

show abstract

Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study

Cited by 29 publications

References 76 publications

Secukinumab: A Review in Psoriatic Arthritis

Secukinumab: A Review in Psoriatic Arthritis

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence

Contact Info

Product

Resources

About